{"name":"Visus Therapeutics","slug":"visus-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPYUVrREZOVmx4Q3NJdkRCajh6dWFuajI5dk5pRFNJcVRqYmJlQm9tVjJiTmpNWVBEcXdNRUVrMElZWnRDT3FTZzhNdjgwN1N0anYtbnlSV1A4QnF6T1FrZEFNTkRyZGl0ZmlTeVp0LVM2QWNvekt6eUVVT2ZfU0QxOTlISDVfdnlUTkM1YzFBaEVSM29wSDNJdkNn?oc=5","date":"2026-01-29","type":"regulatory","source":"Fierce Pharma","summary":"Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow - Fierce Pharma","headline":"Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQUFpyUHM5U0hneHpCMUpvMVdUMU4wc01pYXpjS3R1M3h1Wm56V3c1MDFheXhjT1hGMnFIa25fRFJpdGV3aE9IMWk5YkN5dzZ4TVJoVG9wUXNDMVh2b2tsQ3ItTTNkLVdwUzB0SzlRWEc1UEItaW1iYjV5TWJ1R1RTMQ?oc=5","date":"2026-01-29","type":"regulatory","source":"The Pharma Letter","summary":"FDA approves Tenpoint’s Yuvezzi - The Pharma Letter","headline":"FDA approves Tenpoint’s Yuvezzi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNQnh1YlA3ZkZNdURIY1JJYTJyVVFKVGMySmRBRjh1OVh5M3RWUVV4M3B3dEREcTVHckxmMk0zdEZyXzBjejNWX08tMWxUWUdSaXZHZUVUWGwwTDNRTWIxa0Z2ZEJKYy1kMElGa3R1T1l0a3Nqa1laMFhHTFpVeEE5NWtBSkdBV05ZQzhUajdOQWYwQ2dfelE?oc=5","date":"2026-01-29","type":"regulatory","source":"BioPharma Dive","summary":"Tenpoint wins FDA nod for combination presbyopia eye drop - BioPharma Dive","headline":"Tenpoint wins FDA nod for combination presbyopia eye drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBYQjBDNUJqY3hGVE42OTA2ODZvOEJRM0lzZElGWHJDX2Y1Zno1WXBULWloYkdIRE82SDRPc1FkV2RJMFgxUUZoNHg5dllqVkpBM0lN?oc=5","date":"2026-01-28","type":"regulatory","source":"FirstWord Pharma","summary":"Tenpoint poised to debut new presbyopia drug after FDA nod, fresh capital - FirstWord Pharma","headline":"Tenpoint poised to debut new presbyopia drug after FDA nod, fresh capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPQW1La0c5dG1ReHhvbGdmQXlEdzl1NHQxTEI4dWxVa3F5QmlHUy1lLVhQRUlvQ1dtU25EeWVBajhoSl80cDU4T3dMQXJkMlVYajYyazVFNHdVVVZZbk10YW5paFJlSk9KdTJxUTdCYTBZTWVCeVJ3X1ZPTHREOEswMVY2RTlpZ285Z01DcS1sd3Bqc1lyczNjSkxvUDU3eDJDWnBHdGIyc1hqdFFOTUVScVlxTVRIMm5CNDY1dmJB?oc=5","date":"2025-11-05","type":"pipeline","source":"Optometry Times","summary":"South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia - Optometry Times","headline":"South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPdXlsZ0xMbTh3dWU2M3JFVUZTbXI2dVFDd1Y2aVZmWkpLNlVVTmVKZzNGaVFmUXV2R0FQdWFYZ0tHWGI4ZTIzdXJMTmVWYVdIdnFFOS1IekxCSFF0X0NHanQxelJUeGhteUUzNTVTS1pCdHp0bTRKU08tbDJDYjZxY0dmbmRBRjlucU5TZTljSGFCekgwbjhGUkZkMTNObVc3eTlqTW9BOXRaSjBmTUVHMFYyczBLWU5MOW45MQ?oc=5","date":"2024-12-19","type":"pipeline","source":"VisionMonday.com","summary":"Tenpoint Therapeutics Ltd. Merges With Visus Therapeutics, Inc., Names New CEO - VisionMonday.com","headline":"Tenpoint Therapeutics Ltd. Merges With Visus Therapeutics, Inc., Names New CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQY3BHY2R0WDBkWmZONkR1a2tOV0lvTklyN3BTck1wUEdWVXR2ZENNbnJYY2FjbHY2OHdyc0E5N2xWb2JqbTRfX09YZWNtaDRydDllV01rQXpETkNlMko2WVotSFBiaHhkelFfTEN4Q0ZYSXFuTHJDLWFuOVduRGlQQS1QSmllWmxjYVhPMjNTQ1RHQXFrWUZrWXR0cHhoSzJ6b1J1RkQ5RnRoc2wzY3gxakRnRW94RzBZdFF4Ym1tTW82U1E4aW9zRlBZekJ2Szh0aW5tVC1vTUNQLWJTQkE?oc=5","date":"2024-12-12","type":"deal","source":"Ophthalmology Times","summary":"Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios - Ophthalmology Times","headline":"Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOS0lqb2QydmF3aVJFcldwWVJLNGE1Y2kyZ3BJcFBiYzVPa3YxSXgxWG5CYkRwVG1PSUVHMFBiaUtWZHFqUUNKX3ZuY09Nc1dYYjh3TF9mZkJnelpOTlVHd3VQVlpOYlppM2U1RVRwdGpYYkpidjd4MGpGWDBWRlpCWHg5WDVNSnBZeWpvZ016Qmg3dkcyR3I5bFBsY1p5eDBuNU5hbHZ6UFljUzN3SkNtbmV2dUFTYWY3VENvc2ZpQjhxREFDZXFsSW9hRVVyUDJGOWtrTzY4NGIyVlVXd3RZTG5jM3lic1FQS0EzNnkyaVkwX0Q3azJmS2hzenJnQ1lpRE9fOEQtdG1tZlVob3hzMUJjQ0JkdFBrdHZISkJGSQ?oc=5","date":"2024-12-12","type":"pipeline","source":"Business Wire","summary":"Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines - Business Wire","headline":"Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class O","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaENWMExydzlQUHpZNml3TUExV25NUGxXdkQ0R2g4elVTREI1TlBNWkF5VkxBWUFIakVGQko0N0ZEZ2dwMVE1YzVwY3R1eVMtM1prdi02UHJSZUpHdzAtMDREZi1mbnFOZ3lrNnNTS1VXQmladldvN2ItOWc0QmM4ancyT1J6cy1wR05wT1lZLTFHZHRXOXUxQkpUQjA5TEgteVUycG5XU0l5MnY5OEtKc2dkOEQyMjhNemV5T3Q2Nm4?oc=5","date":"2024-12-12","type":"regulatory","source":"Fierce Biotech","summary":"Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line - Fierce Biotech","headline":"Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNSmtnbnEyb3g3QnNWWWd1cFFaRFB3bkpIVllMa28tVlJvWHJqQmtYUmtUOUFiOXU5VkxiMWo2RDlvRlBHQV82SzlCMUx4WThDd1lyVE4ydkNWSGFjcXJkZ09maTBSSWoxQnJQRUJXYXE2RWVCeTd3cW5VbUlaeTRocEhaZHVjRW1SSlplanJwbUpsYTl3dU9fVHY4TDdaNnVSOTlKOVJZaFU3SzBVZ3dMUEVReFBLTmM0ZGFyYlczVU12QXYxbmJNZjNSUXBqMzhBSWxXdTl3ZUM?oc=5","date":"2024-12-12","type":"pipeline","source":"Eyes On Eyecare","summary":"Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements - Eyes On Eyecare","headline":"Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNWWZUTVVwVkN5T3R3VWxMb3hhYWdGZWZEOWZPSHpiYjNiM0RPcmQtRWI2ZHVjOFpaTWl0RDB6aHJGZDJuQnpmUE01WHcwZ1ZDZkVJZjBuWUZ5QTFVYzB5bk1QMkFSQ1JHcGttd3FGUnJhRnRuZVBVNmNTR0hyTVc4X3JuTTBKWnBjRlpha2xWbk1VUQ?oc=5","date":"2024-12-12","type":"pipeline","source":"The Pharma Letter","summary":"Tenpoint and Visus unite ahead of presbyopia drop filing - The Pharma Letter","headline":"Tenpoint and Visus unite ahead of presbyopia drop filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxONFFQWWFfbS1mNGR3X0tCR2wxWTRHdTY0Qm82QkNMTFlDVG1maERpbC15NDR6QVNXMmxONTgxQmZxXzRGZWkyeGl6N3JHMjlELV9GdGFYNlJRY2hONmx6RjJPLXJTMi1faGZUMXBxVkFHRU5aOGMtc1Bta25YeW1OVkVheWlReWhSeDVXQ2pLeUVtQ0NKR2NtU0RJcndocW1IVHFsSU8tTUx2R0RQOTl6ak10UzZtQldhRU92Q1RsMVZjalBUc0dERGI5ckVoX0VoYmxtM25kQVVmNGNTZ1g3VlA4TXNCVmhDMzJ0RmlPVWd4bHh5RkYxS09HTy1sRmZFTG1nTFc0YWFrcE5hVkRhZw?oc=5","date":"2021-08-10","type":"deal","source":"Business Wire","summary":"Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners - Business Wire","headline":"Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Par","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}